TMO

Thermo Fisher Scientific Inc.

Next est. report 2026-10-28 · BMO

Biotech '26: AI Driven Drug DiscoveryGenomics '25: Genomics Tools & AutomationGenomics '25: Sequencing HardwareMedTech Long '24: Lab & Life Sciences Tools MedTech Long '26: CROs MedTech Long '26: Life Science Tools & BioprocessingRegulatory Testing '26: Life Sciences & Lab Tests

Loading…

Overview

Thermo Fisher Scientific Inc. is a global leader providing scientific services, including life sciences solutions, analytical instruments, and specialized diagn

Thermo Fisher Scientific Inc. is a global leader providing scientific services, including life sciences solutions, analytical instruments, and specialized diagnostics. Its largest segment, Laboratory Products and Biopharma Services (~49%), now enhanced by the integrated Clario acquisition for digital clinical trial solutions, serves pharmaceutical, biotech, academic, and clinical labs, helping them advance research and develop drugs. The company is actively managing its portfolio, including a pending divestiture of its microbiology business.

What They Do (Plain English & Analogies): Thermo Fisher Scientific is like the 'everything store' and 'general contractor' for the scientific world. If you're a scientist, a drug company, or a hospital, they provide almost everything you need to do your work. This ranges from basic lab supplies like pipettes and chemicals to highly advanced scientific instruments such as mass spectrometers and electron microscopes. They also offer outsourced services to help run clinical trials for new drugs and even manufacture those drugs. Essentially, they provide all the 'picks and shovels' that make scientific research, drug discovery, and manufacturing possible, but they don't typically create the drugs themselves. Their mission is to enable customers to make the world healthier, cleaner, and safer.
Very Brief History: Founded in 1956 as Thermo Electron, the company underwent a significant transformation with its 2006 merger with Fisher Scientific. Over the past two decades, it has grown through strategic acquisitions, including Life Technologies (genomics) in 2014, Patheon (drug manufacturing) in 2017, PPD (clinical research) in 2021, and most recently, Clario (digital clinical trials) in March 2026. This evolution has shifted the company from primarily a hardware manufacturer to an end-to-end service provider for the life sciences industry.
"Street Stereotype": Thermo Fisher Scientific is widely regarded by analysts as a 'Quality Compounder' and one of the best-managed companies in the healthcare sector. It is known for its 'PPI Business System' (Practical Process Improvement), a lean-management philosophy that helps it consistently expand margins and successfully integrate large acquisitions. Investors often view it as a 'safe haven' with a high-quality management team capable of navigating macroeconomic challenges effectively.
Subsidiaries On Linked In*: Thermo Scientific
Applied Biosystems
Invitrogen
Fisher Scientific — Part of Thermo Fisher Scientific
Unity Lab Services
Patheon
PPD — Clinical research business of Thermo Fisher Scientific
Gibco
Ion Torrent
Molecular Probes
Clario — Acquired in March 2026
Customer Sectors & Example Clients: Thermo Fisher Scientific serves a diverse range of customer sectors, including Pharma & Biotech (approximately 60% of revenue), Academic & Government, Industrial & Applied, and Diagnostics & Healthcare. Example clients include global pharmaceutical companies such as Pfizer, Novartis, and AstraZeneca; biotech innovators like Amgen and Moderna; and major research institutions such as the National Institutes of Health (NIH) and Harvard University. They also collaborate with organizations like Precision Health Research Singapore for population health studies.
New Customers / Segments They'Re Targeting: Thermo Fisher is actively targeting customers seeking accelerated drug development, particularly in the pharma and biotech sectors, by offering integrated solutions that span from early development through clinical trials and manufacturing. The acquisition of Clario enhances their ability to provide digital endpoint data solutions, appealing to customers looking for deeper clinical insights and improved drug development productivity. They are also expanding their bioprocess design centers to work side-by-side with pharma and biotech customers to optimize manufacturing processes.
Supply Chain And Sourcing Geographies: Thermo Fisher Scientific operates with a global supply base, providing raw materials, lab equipment, chemicals, and other vital goods for its worldwide manufacturing and service network. The company has over 60 Pharma Services locations across 25 countries, including significant manufacturing presence in the U.S. (e.g., North Carolina, Missouri, Massachusetts) due to reshoring initiatives. They also have operations and supplier onboarding processes in Europe, including Germany, Switzerland, and Norway. The company emphasizes a resilient supply chain and responsible sourcing practices globally. They recently opened a flagship U.S. bioprocess design center in Massachusetts.
Sales Geographies And Expansion Plans: The company sells its products and services across North America, Europe, Asia-Pacific, and other international markets. In Q2 2026, North America grew low single digits, Europe grew high single digits, and Asia Pacific grew high single digits, with China growing low single digits. While the company is encouraged by the return to growth in China, it remains a muted environment for academic and government sectors within the region. Management continues to monitor the situation in China and plans to spend more time there in the second half of the year. They are expanding their global network of collaborative innovation centers, such as the U.S. bioprocess design center in Massachusetts.
How Key Themes May Help/Hurt: The buildout of 'AI Driven Drug Discovery' is a significant tailwind for Thermo Fisher Scientific. The company is actively integrating AI into its offerings, such as AI-driven capabilities in its new Orbitrap platforms and expanding suite of AI-powered software for smarter workflows and accelerated proteomics research. Collaborations with entities like Precision Health Research Singapore, combining Olink technology with Orbitrap Astral mass spectrometry, are advancing precision medicine through integrated proteomics capabilities. AI is also being deployed across the company through its PPI Business System to further accelerate its impact. This focus on AI-enabled innovation allows customers to accelerate scientific discovery and advance their work, which directly benefits TMO's instrument and software sales. The company's 'trusted partner' status is enhanced by providing cutting-edge AI tools that help customers solve complex challenges and accelerate drug development, aligning with the bullish trend of AI reducing drug development timelines and costs.

3 Main Long-Term Bull Details

High-Impact Innovation and AI Integration: Thermo Fisher's continuous investment in high-impact innovation, including next-generation mass spectrometers, UHPLC systems, and AI-driven software, enables customers to accelerate scientific discovery and advance their work. The strategic integration of AI across its portfolio, from instruments to internal operations via the PPI Business System, solidifies its leadership and drives market share gains.
Trusted Partner Status and Comprehensive Offerings: The company's established 'trusted partner' status, enhanced by its unparalleled commercial engine and integrated offerings like accelerated drug development, resonates strongly with pharma and biotech customers. Acquisitions like Clario further strengthen its position in clinical research and digital endpoint solutions, driving customer success and improving drug development productivity.
Operational Excellence and Strategic Capital Deployment: The PPI Business System consistently drives strong operational performance, leading to margin expansion and efficient capital deployment. This, combined with a disciplined M&A strategy focused on strategic acquisitions that enhance capabilities and return of capital to shareholders, creates long-term value for stakeholders.

3 Main Long-Term Bear Details

Macroeconomic Headwinds and Geopolitical Tensions: Persistent muted demand in academic and government sectors, particularly in the U.S. and China, continues to pressure R&D spending. Geopolitical tensions and conflicts, such as those in the Middle East, introduce additional complexity and contribute to ongoing tariff and FX headwinds, potentially impacting operating margins.
Inflationary Pressures and Margin Management: The broader macroeconomic environment is expected to create modest inflationary pressure. While the PPI Business System aims to mitigate these impacts, significant or sustained inflation could challenge the company's ability to fully offset cost increases and maintain consistent margin expansion.
Divestiture Impact and Integration Risks: While the divestiture of the microbiology business reflects active portfolio management, it will reduce 2026 revenue and adjusted EPS. Additionally, despite smooth progress, the integration of large acquisitions like Clario and the filtration and separation business always carries inherent risks in fully realizing anticipated synergies and maintaining business momentum.

Competitors And Differentiation: Thermo Fisher Scientific competes with a range of companies in the life sciences tools, diagnostics, and biopharmaceutical services sectors. Their differentiation strategy is built on several pillars: high-impact innovation, their trusted partner status with customers, and an unparalleled commercial engine. They continuously launch new technologies, such as next-generation Orbitrap mass spectrometers and AI-driven software, to help scientists solve complex analytical challenges. Their PPI Business System drives operational excellence and productivity, while strategic acquisitions like Clario enhance their capabilities in areas like digital clinical trials. The company's integrated offerings, such as accelerated drug development, provide a competitive advantage by allowing customers to streamline their programs from development to clinical trials and manufacturing.
Recent Performance & What The Market'S Focused On: Thermo Fisher delivered an outstanding second quarter in 2026, with revenue growing 10% to $11.99 billion and adjusted EPS growing 13% to $6.03 per share. Organic revenue growth was 5%, significantly ahead of previous guidance. Customer activity strengthened across all end markets, with pharma and biotech showing mid-single-digit growth, academic and government growing low single digits, industrial and applied growing mid-single digits, and diagnostics and healthcare growing mid-single digits. The company raised its full-year 2026 revenue guidance to a range of $47.4 billion to $48.1 billion and adjusted EPS guidance to $24.93 to $25.33, reflecting strong Q2 performance and an improved outlook for the second half, while also incorporating the expected impact of the microbiology business divestiture. The market is focused on the continued strengthening of customer activity across end markets, particularly in pharma and biotech, the successful integration and performance of recent acquisitions like Clario, and the company's ability to achieve its raised full-year organic revenue and adjusted EPS guidance.

Revenue Segments And Estimated Mix: Life Sciences Solutions — Mix: ~22% (based on 2025); Source: Existing knowledge (2025), Q2 2026 transcript; Trend: Q2 reported revenue increased 13% versus prior year, organic revenue growth was 3%
Analytical Instruments — Mix: ~16% (based on 2025); Source: Existing knowledge (2025), Q2 2026 transcript; Trend: Q2 reported revenue and organic revenue increased 7% versus prior year
Specialty Diagnostics — Mix: ~10% (based on 2025); Source: Existing knowledge (2025), Q2 2026 transcript; Trend: Q2 reported revenue grew 6% year-over-year, organic revenue grew 5%
Laboratory Products and Biopharma Services — Mix: ~49% (based on 2025); Source: Existing knowledge (2025), Q2 2026 transcript; Trend: Q2 reported revenue increased 12% and organic revenue growth was 5%
Product Brands: Thermo Scientific
Applied Biosystems
Invitrogen
Fisher Scientific
Unity Lab Services
Patheon
PPD
Gibco
Ion Torrent
Molecular Probes
Clario
Glacios 3 Cryo-TEM
TSQ Certis Triple Quad Mass Spectrometer
Niton XL5E handheld XRF analyzer
Gibco CTS Compleo fill and finish system
FluidEase Pro ClipTip electronic pipettes
Orbitrap Tribrid Apex mass spectrometer
Orbitrap Excedion mass spectrometer
Vanquish Amplify UHPLC system
PowerFlex thermal cycler
Olink

Bull / Bear Details

Thermo Fisher remains the premier 'trusted partner' in life sciences, demonstrating robust execution and strategic growth. The thesis is bullish, driven by outs

Thesis

Thermo Fisher remains the premier 'trusted partner' in life sciences, demonstrating robust execution and strategic growth. The thesis is bullish, driven by outstanding Q2 performance, further raised 2026 guidance (now 9-11% adjusted EPS growth), and strengthening customer activity across all end markets. TMO's high-impact innovation, successful Clario integration, and AI deployment via the PPI business system position it for continued market share gains and long-term growth, despite ongoing stabilization in academic markets. (Updated 2026-07-24)

Bull case

TMO's high-impact innovation, including new Orbitrap platforms with AI-driven capabilities and advanced UHPLC systems, solidifies its leadership in research. Active AI deployment across the PPI business system and new product launches accelerate scientific discovery, enhance competitive advantage, and drive market share gains, particularly in complex analytical challenges and proteomics research.
Strengthening customer activity across all end markets, notably mid-single-digit growth in Pharma and Biotech and a return to low single-digit growth in Academic and Government, signals a broad market recovery. The successful integration and strong performance of the Clario and Filtration & Separation acquisitions further enhance TMO's capabilities, contributing significantly to revenue and EPS.
TMO delivered an outstanding Q2 with 5% organic revenue growth and 13% adjusted EPS growth, leading to raised full-year 2026 guidance (upper end of 3-4% organic growth, 9-11% adjusted EPS growth). The PPI Business System continues to drive operational efficiency, enabling 90 basis points of adjusted operating margin expansion in Q2 and effectively mitigating potential cost pressures.

Bear case

While China returned to low single-digit growth, its academic and government sector remains muted and not improving. The U.S. academic and government market, despite returning to growth, is still in a "stabilization period." This indicates that broad-based, strong recovery in these key segments is not yet fully confirmed, potentially limiting upside to overall organic growth.
The pending divestiture of the microbiology business, expected to close in Q3, will reduce 2026 revenue by approximately $200 million and adjusted EPS by $0.05. Additionally, while Pharma Services anticipates a stronger second half, management noted this doesn't guarantee sequential Q4 growth over Q3, introducing potential quarter-to-quarter revenue variability.
Despite strong performance, the bioproduction space remains highly competitive with numerous players. While TMO emphasizes its differentiated capabilities and share gains, sustained competitive pressure or unforeseen execution challenges in scaling new technologies or integrating acquisitions could impact future growth and margin expansion, particularly if market conditions become less favorable than anticipated.

Bull / Bear Case

Bear Case: Despite a strong Q1, Thermo Fisher faces persistent macroeconomic headwinds, particularly muted demand in the U.S. academic and China markets, which continue to pressure R&D spending and resulted in low-single-digit declines in these segments. Geopolitical tensions and ongoing tariff/FX headwinds further complicate the operating environment and impact margins. The company anticipates higher inflationary pressures in future quarters, posing a risk to profitability and challenging margin expansion targets, even with the PPI Business System. Critically, the updated 2026 guidance relies on a significant acceleration in organic revenue growth in the second half of the year, following a modest 1% in Q1, introducing execution risk if market recovery or internal performance lags expectations.
Bull Case: Thermo Fisher Scientific demonstrates resilience and strategic execution, driven by strong Q1 performance and raised 2026 guidance for both revenue and adjusted EPS. The successful and accretive acquisition of Clario significantly enhances its clinical research capabilities, reinforcing its "trusted partner" status in drug development. High-impact innovation, including AI-enabled Cryo-TEMs and new mass spectrometers, coupled with strategic collaborations with NVIDIA and OpenAI, solidifies its leadership in advanced research and accelerates scientific discovery. The robust PPI Business System consistently drives operational efficiency, enabling effective mitigation of macro complexities and inflationary pressures. Furthermore, the bioproduction business continues to deliver excellent organic growth, poised to benefit from future biopharma reshoring tailwinds in 2027-2028.
More Compelling & Why: Bear. While TMO is a quality compounder, its forward P/E of approximately 28x appears fair to slightly stretched given the significant back-half weighting of its 2026 organic revenue growth guidance (1% in Q1, ~3% in Q2, implying a much higher H2). The strongest argument for the bear case is the execution risk associated with this ramp, coupled with persistent muted demand in China and U.S. academic markets, and new inflationary pressures. My view would flip to bullish if TMO demonstrates organic revenue growth above 3% in Q2 and provides clearer evidence of sustained recovery in its challenged end markets, justifying a premium valuation.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Clinical Research Organic Growth & Clario Acquisition Contribution Update	Strong performance in clinical research and successful Clario integration are crucial for TMO's largest segment, validating its 'trusted partner' status and driving accretive EPS growth in drug development.	Organic revenue growth in the Laboratory Products and Biopharma Services segment (which includes Clinical Research) for Q3 2026. Management commentary on Clario's integration progress and its contribution to full-year 2026 revenue and adjusted EPS, which is now expected to be $1.6 billion and $0.32, respectively.	Bullish if Laboratory Products and Biopharma Services organic growth for Q3 2026 is at or above 5% (Q2 2026 level) and management reaffirms or raises the full-year 2026 acquisition contribution (including Clario) of $1.6 billion revenue and $0.32 adjusted EPS. Bearish if organic growth decelerates below 5% or acquisition contribution guidance is lowered.	Thermo Fisher Scientific Q3 2026 Earnings Call and Press Release (expected October 2026).	Industry news on CRO market trends (e.g., FierceBiotech, BioSpace), biotech funding announcements.	Thinknum: Clinical Research job postings growth; Reorg Research: Biotech funding rounds.
Full-Year 2026 Organic Revenue Growth Outlook Confirmation	This is the primary indicator of core business health, confirming the post-pandemic bioprocessing slump has ended and validating the full-year guidance ramp, especially the 4% organic growth expected for the second half of 2026.	Reported total company organic revenue growth for Q3 2026 and management's reaffirmation or adjustment of the full-year 2026 organic revenue growth guidance (upper end of 3-4%, with H2 at 4%).	Bullish if Q3 2026 total company organic revenue growth is at or above 4% and management reaffirms the full-year 2026 organic growth at the upper end of 3-4% (implying 4% for H2). Bearish if Q3 2026 organic growth is below 4% or full-year guidance is lowered.	Thermo Fisher Scientific Q3 2026 Earnings Call and Press Release (expected October 2026).	Industry reports on life science tools market growth (e.g., EvaluatePharma, Grand View Research).	Bloomberg Terminal: Consensus revenue estimates for TMO.
Bioproduction Business Organic Growth Momentum	Bioproduction is a key growth driver within Life Sciences Solutions, signaling robust recovery and future tailwinds from biopharma reshoring, and demonstrating TMO's competitive strength.	Management commentary on the organic growth performance of the Bioproduction business within the Life Sciences Solutions segment for Q3 2026.	Bullish if management reports continued 'excellent organic growth' for the Bioproduction business in Q3 2026, or if the Life Sciences Solutions segment organic growth is above 3% (Q2 2026 level). Bearish if management indicates a deceleration in bioproduction growth or if Life Sciences Solutions segment organic growth is at or below 3%.	Thermo Fisher Scientific Q3 2026 Earnings Call and Press Release (expected October 2026).	Industry news on biopharma manufacturing capacity expansion, adoption of single-use technologies (e.g., BioProcess International).	S&P Global Market Intelligence: Biopharma manufacturing project tracking; EvaluatePharma: Bioprocessing market analysis.
China End Market Organic Revenue Growth Trend	China represents a significant portion of revenue (7.5%). A sustained return to growth indicates overcoming macro headwinds and provides potential upside to overall guidance.	Organic revenue growth reported for China in Q3 2026.	Bullish if China organic revenue growth for Q3 2026 is above low single digits (Q2 2026 level). Bearish if China organic revenue growth for Q3 2026 is flat or declines.	Thermo Fisher Scientific Q3 2026 Earnings Call and Press Release (expected October 2026).	China's National Bureau of Statistics: GDP, industrial production data; Caixin PMI.	Wind Financial Terminal: China economic and industry-specific data; CEIC Data: China R&D spending.
Adjusted Operating Margin Expansion & Inflation Mitigation	Demonstrates the effectiveness of the PPI Business System in driving productivity and offsetting cost pressures, protecting profitability and supporting EPS growth, crucial for TMO's 'Quality Compounder' status.	Reported adjusted operating margin percentage for Q3 2026 and management commentary on the effectiveness of PPI initiatives in offsetting inflation, and reaffirmation of the full-year 2026 adjusted operating margin expansion guidance (now 80 basis points).	Bullish if Q3 2026 adjusted operating margin expands year-over-year and management reaffirms the full-year 2026 adjusted operating margin expansion guidance of 80 basis points. Bearish if Q3 2026 adjusted operating margin contracts year-over-year or full-year margin expansion guidance is lowered.	Thermo Fisher Scientific Q3 2026 Earnings Call and Press Release (expected October 2026).	U.S. Bureau of Labor Statistics: Producer Price Index (PPI) for manufacturing; global supply chain indices (e.g., ISM Manufacturing PMI).	FactSet: Margin analysis and consensus estimates; Bloomberg Terminal: Commodity price trends and inflation forecasts.

Key Reported Metrics, Reratings Triggers & Results3 rows

This segment, now including Clario, is TMO's largest and a key driver of the CRO thesis. Strong organic growth here, particularly from clinical research and bio

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Laboratory Products and Biopharma Services Organic Revenue Growth	4%	This segment, now including Clario, is TMO's largest and a key driver of the CRO thesis. Strong organic growth here, particularly from clinical research and bioproduction, signals successful integration and market share gains.	For Thermo Fisher Scientific Inc. to rerate higher, the Laboratory Products and Biopharma Services Organic Revenue Growth metric needs to accelerate to 6% or higher. This would represent a significant increase from its current 4% (Q1 2026) and align with the 'bullish' signal for Clinical Research organic growth exceeding mid-single digits. Additionally, positive commentary on the integration and revenue contribution from the recently acquired Clario is crucial. This strong performance in its largest segment would be essential for the company to achieve its overall full-year 2026 organic revenue growth rerating threshold of 4.5% or higher.	Achieving 6%+ organic growth in this segment, especially with successful Clario integration, validates TMO's 'trusted partner' status and market share gains in drug development. It signals a robust recovery in biopharma services, justifying a premium valuation and confirming the company's ability to drive sustainable growth despite macro headwinds.	2026-07-23
Adjusted EPS	6%	This metric demonstrates Thermo Fisher's ability to maintain profitability through its PPI Business System despite macroeconomic headwinds. A return to double-digit EPS growth is a key rerating threshold.	For Thermo Fisher Scientific Inc. (TMO) to rerate higher, Adjusted EPS growth must hit or exceed 10% for the full year 2026, implying a target of $25.25 or higher. This would necessitate management raising their current full-year guidance of 8-10% ($24.64-$25.12). Additionally, this must be accompanied by evidence that the Clario acquisition will contribute more than the projected $0.20-$0.25 in the second half of the year.	A return to double-digit Adjusted EPS growth is the psychological threshold for TMO to regain its 'premium compounder' status. It would demonstrate the effectiveness of the PPI business system in offsetting macroeconomic headwinds and confirm a robust bioprocessing recovery, justifying a rerating of valuation multiples back toward historical 25x+ levels.	2026-07-23	$6.03 (13% y/y growth); Full-year guidance raised to $24.93-$25.33 (9-11% growth); Acquisitions expected to contribute $0.32 of adjusted EPS for the year.	Yes	Adjusted EPS grew 13% year-over-year to $6.03 in Q2. The company raised its full-year adjusted EPS guidance to a range of $24.93 to $25.33, representing 9% to 11% growth over 2025. The upper end of this new guidance ($25.33) exceeds the rerating target of $25.25, and the growth range includes the 10% threshold. Furthermore, acquisitions, including Clario, are now expected to contribute $0.32 of adjusted EPS for the full year, surpassing the previous projection for Clario's second-half contribution.
Organic Revenue Growth	1%	This is the primary indicator of core business health, stripping out FX and M&A. Investors are watching for sustained acceleration to confirm the post-pandemic bioprocessing slump has ended and to validate the full-year guidance ramp.	To trigger a positive rerating, Thermo Fisher Scientific (TMO) needs to deliver organic revenue growth at or above 4.5% for the full year 2026, exceeding the high end of its 3-4% guidance. Additionally, the company must report Q1 2026 organic growth of 2.5% or higher (beating its 1-2% 'low bar' guidance), demonstrate that China organic growth has stabilized to at least 0% (up from mid-single-digit declines), and achieve a bioprocessing book-to-bill ratio exceeding 1.1x.	TMO currently trades at a discount due to skepticism regarding bioprocessing recovery and China headwinds. Achieving 4.5%+ organic growth validates conservative guidance, confirms market share gains, and provides visibility for the stock to return to a premium forward P/E multiple of 25x+. This metric is a primary indicator of core business health.	2026-07-23	5% (Q2 2026 organic growth); Full-year guidance raised to upper end of 3-4% (i.e., 4%); China grew low single digits.	Partially	Thermo Fisher reported strong Q2 organic revenue growth of 5%, a significant acceleration from the prior quarter's 1%. The company raised its full-year organic revenue growth guidance to the upper end of its 3-4% range, implying 4%. While China returned to low single-digit growth, meeting one aspect of the trigger, the full-year organic growth guidance of 4% did not meet the rerating threshold of 4.5% or higher.

Key Questions

Can Thermo Fisher sustain the strong Q2 organic revenue growth of 5% and achieve the upper end of its raised 3-4% full-year organic growth guidance, particularl

Can Thermo Fisher sustain the strong Q2 organic revenue growth of 5% and achieve the upper end of its raised 3-4% full-year organic growth guidance, particularly with the expectation of 4% organic growth in the second half?

Question 2: Will the observed strengthening in pharma and biotech, alongside the return to growth in academic and government markets, prove durable enough to drive a broad-based market recovery, especially given the still muted academic and government spending in China?
Question 3: Beyond the successful integration of Clario and the effectiveness of the PPI business system in expanding operating margins, how will the pending divestiture of the microbiology business and ongoing FX headwinds impact profitability and capital deployment in the second half of 2026?

Earnings Transcript Summary3 rows

2026-07-23 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. Executing Proven Growth Strategy: Management is focused on enhancing capabilities, advancing trusted partner status with customers, and driving share gain through high-impact innovation, industry-leading commercial capabilities, and customer success. This includes launching new technologies like next-generation Orbitrap platforms and AI-driven capabilities in mass spectrometry, and the Applied Biosystems PowerFlex thermal cycler. 2. Leveraging the PPI Business System: The company is actively managing operations, leveraging its global scale and the strength of its PPI business system to create value, improve quality, productivity, and customer allegiance, and deploy AI across the company to accelerate PPI's impact. 3. Disciplined Capital Deployment: Management continues to execute a disciplined approach to capital deployment, combining strategic M&A (like the successful integration of Clario and Filtration and Separation businesses) and returning capital to shareholders (such as the $1 billion share repurchase in Q2).	The overall takeaway from the call is that Thermo Fisher Scientific delivered an outstanding second quarter, exceeding expectations on both the top and bottom lines. The company raised its full-year revenue and adjusted EPS guidance, reflecting strong operational performance and an improved outlook for the second half of the year. Management highlighted strengthening customer activity across all end markets, particularly in pharma and biotech, and the successful integration and performance of recent acquisitions. The tone of the call was highly positive, confident, and disciplined, emphasizing the effectiveness of their proven growth strategy, high-impact innovation, and the PPI business system in driving share gains and creating value.	Life Sciences Solutions: Q1 2026 reported revenue increased 13% (organic revenue growth was 1%). (Reported growth was stable, organic growth accelerated). Analytical Instruments: Q1 2026 reported revenue was flat (organic revenue decreased 2%). (Growth accelerated significantly on both reported and organic bases). Specialty Diagnostics: Q1 2026 reported revenue declined 1% (organic revenue declined 3%). (Growth accelerated significantly on both reported and organic bases). Laboratory Products and Biopharma Services: Q1 2026 reported revenue increased 7% (organic growth was 4%). (Reported growth accelerated, organic growth accelerated).	1. Strengthening Customer Activity and End Market Drivers: Analysts inquired about the specific drivers behind the strengthening customer activity across end markets. Management responded that customer activity picked up across all end markets, with significant progression in the pharma and biotech customer base (which accounts for about 60% of revenue), and a return to growth in academic and government markets. 2. Second Half Guidance and Phasing: Analysts questioned the full-year organic growth guidance, particularly the expectation for similar organic growth in Q3 and Q4 after a 3% growth in the first half. Management clarified that they expect organic growth to step up to 4% in the second half, with a modest improvement to the outlook, and the quarterly phasing is not meaningfully changed from original assumptions. 3. Performance of Services Businesses (PPD, Clario, Patheon) and Biotech Funding: Analysts sought more details on the performance of PPD, the integration and contribution of Clario, and the Patheon business, as well as whether biotech funding is translating into spending. Management stated that clinical research had an excellent quarter with strong organic growth in revenue and authorizations, driven by improving market conditions. Clario had a very strong first full quarter of ownership, contributing positively to acquisitions. Patheon experienced modest growth in Q2, with stronger performance expected in the second half due to shipping activity and reshoring wins.	Life Sciences Solutions: reported revenue increased 13% (organic revenue growth was 3%). Analytical Instruments: reported revenue increased 7% (organic revenue increased 7%). Specialty Diagnostics: reported revenue grew 6% (organic revenue grew 5%). Laboratory Products and Biopharma Services: reported revenue increased 12% (organic revenue growth was 5%).

2026-04-23 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. Executing Proven Growth Strategy: Management is focused on advancing its leadership position through high-impact innovation (e.g., new Cryo-TEM, mass spectrometers, pipettes), strengthening its trusted partner status with customers (e.g., NVIDIA collaboration, SHL Medical partnership, accelerated drug development offering), and leveraging its unparalleled commercial engine (e.g., new Cryo-EM Drug Discovery Center). 2. Leveraging the PPI Business System: The company is actively managing operations through its PPI Business System to drive accelerated cost productivity, deploy AI at scale to run the company better, and mitigate tariffs, especially in the context of potential inflationary pressures. 3. Disciplined Capital Deployment: Management continues to execute a disciplined approach combining strategic M&A (completing the acquisition of Clario, progressing with the filtration and separation business from Solventum) and returning capital to shareholders (repurchasing $3 billion of shares, increasing dividend by 10%).	The overall takeaway from the call is that Thermo Fisher Scientific delivered a strong start to 2026, with Q1 performance aligning with expectations. The company raised its full-year revenue and adjusted EPS guidance, reflecting the strong operational performance and the acquisition of Clario. Management expressed confidence in their end markets, particularly pharma and biotech, and their ability to navigate macroeconomic complexities, including potential inflationary pressures, by leveraging their PPI Business System and strategic initiatives. The tone was positive, confident, and disciplined, emphasizing continued execution of their growth strategy, high-impact innovation, and strategic capital deployment.	Life Science Solutions: Q4 2025 reported +13% (Organic +4%). Growth in Q1 2026 was stable on a reported basis but decelerated organically. Analytical Instruments: Q4 2025 reported +1% (Organic Flat). Growth in Q1 2026 decelerated on both reported and organic bases. Specialty Diagnostics: Q4 2025 reported +5% (Organic +3%). Growth in Q1 2026 decelerated on both reported and organic bases. Laboratory Products and Biopharma Services: Q4 2025 reported +7% (Organic +5%). Growth in Q1 2026 was stable on a reported basis but decelerated organically.	1. Full-Year Organic Growth Ramp: Analysts questioned the confidence in the acceleration needed to hit the full-year guidance, given Q1's 1% organic growth and the projected ramp. Management responded that the ramp is not due to a change in underlying market conditions but rather factors like comparable selling days (Q1 had one less selling day, Q4 has a tailwind) and revenue phasing in Pharma Services, which is expected to deliver much stronger growth in the second half. 2. Biopharma/PPD Performance and Biotech Funding: Analysts inquired about PPD's bookings, whether biotech funding is translating into spending, and early feedback on the Clario acquisition. Management stated that Clinical Research had an excellent quarter with strong organic growth in both revenue and authorizations, indicating continued share gains. They noted that the biotech funding environment is improving, and customer sentiment is strengthening. Early feedback on Clario is very positive, with customers excited about its technology. 3. AI Adoption and Instrument Innovation: Analysts asked about AI's influence on customer spending and potential new offerings. Management highlighted AI's role in accelerating scientific discovery, deepening understanding, and improving returns on investment for the drug development industry. They see AI as a significant positive for Thermo Fisher, enhancing its portfolio and competitive advantage through collaborations like NVIDIA and OpenAI, and making instruments more automated and data-ready.	Life Sciences Solutions: reported revenue increased 13% (organic revenue growth was 1%). Analytical Instruments: reported revenue was flat (organic revenue decreased 2%). Specialty Diagnostics: reported revenue declined 1% (organic revenue declined 3%). Laboratory Products and Biopharma Services: reported revenue increased 7% (organic growth was 4%).

2026-01-29 · 2025Q4 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. PPI Business System: Management is emphasizing the use of their Practical Process Improvement (PPI) system to drive operational excellence, manage cost bases, and mitigate macro headwinds like tariffs and FX volatility. 2. High-Impact Innovation: Focus on launching breakthrough products such as the Orbitrap Astro Zoom and Helios MX-one to drive market share gains and meet evolving customer needs in precision medicine and semiconductors. 3. Strategic Capital Deployment: Executing a disciplined M&A strategy, specifically the $13 billion committed in 2025 (including Clario and Solventa's filtration business), to enhance their 'trusted partner' status and expand into high-growth digital endpoint data solutions.	The takeaway is that Thermo Fisher ended 2025 with strong momentum, delivering a significant Q4 beat on both top and bottom lines despite macro volatility. The tone was highly confident and disciplined. Management is positioning 2026 as a year of 'controlling their own destiny' through productivity and share gains, even while assuming conservative market conditions in China and academic sectors.	Based on Q3 2025 results: Life Science Solutions: +2% (Organic 0%); Analytical Instruments: +1% (Organic 0%); Specialty Diagnostics: +4% (Organic +2%); Laboratory Products and Biopharma Services: +3% (Organic +2%). Growth accelerated significantly in Life Science and Lab/Biopharma segments in Q4.	1. 2026 Organic Growth Guidance: Analysts questioned the confidence in accelerating from 2% organic growth in 2025 to a 3-4% range in 2026. Management responded that 2025 was impacted by a 1% pandemic-related runoff; excluding that, the underlying growth was 3%, making the 2026 target a prudent continuation of current momentum. 2. Biopharma Sentiment and Budgets: Analysts asked if improved funding and sentiment are translating to actual spending. Management noted that while there is a lag, the tone from January customer meetings is very positive, and biotech funding is starting to flow into authorizations. 3. Macro Headwinds (Tariffs and China): Analysts pressed on the impact of trade tensions and the weak China market. Management stated they have successfully managed over 100 basis points of tariff/FX headwinds through PPI and are assuming 'similar conditions' for China in their 2026 guidance to remain conservative.	Life Science Solutions: +13% (Organic +4%); Analytical Instruments: +1% (Organic Flat); Specialty Diagnostics: +5% (Organic +3%); Laboratory Products and Biopharma Services: +7% (Organic +5%).

Transcript Tidbits4 rows

2026-07-23

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Thermo Fisher completed the acquisition of Clario, which enhances its ability to deliver deeper clinical insights to pharma and biotech customers through market-leading digital endpoint data solutions. The company opened its flagship U.S. bioprocess design center in Massachusetts, expanding its global network of collaborative innovation centers. A strategic collaboration with Precision Health Research Singapore was announced to advance population scale research using integrated proteomics capabilities, including Olink technology and the Orbitrap Astral mass spectrometry platform. New product launches include the Thermo Scientific Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, the Thermo Scientific Vanquish Amplify UHPLC system, and the Applied Biosystems PowerFlex thermal cycler, all designed to accelerate scientific discovery and improve workflows.	Thermo Fisher's proven growth strategy, high-impact innovation, trusted partner status, and unparalleled commercial engine are driving share gains and strengthening its industry leadership. The clinical research business delivered strong organic growth in both revenue and authorizations, indicating continued market success. The bioproduction business, a leader in cell culture media and single-use technologies, demonstrated excellent organic growth due to its differentiated capabilities. The filtration and separation business is performing very well, with strong demand and plans to increase capacity. The DynaDrive single-use bioreactors are becoming standardized across the CDMO landscape, indicating a competitive advantage in efficient production.	Customer activity across all end markets continued to strengthen during the second quarter, with encouraging progression in the pharma and biotech customer base, including a clear pickup in biotech spending. The clinical research market conditions are improving. Large pharma executives express excitement about their pipelines and feel confident in navigating macro factors like the IRA, MFNs, and tariffs. There is good government support for academic research in the U.S., contributing to market stabilization. The bioproduction space is identified as a key enabling technology, especially with the shift towards single-use technologies in the pharmaceutical and biotech industry. Higher commodity prices and increased demand for safety and security applications are driving growth in the Chemical Analysis business.	Thermo Fisher is raising its full-year 2026 guidance for both revenue and adjusted EPS, reflecting strong Q2 performance and an improved outlook for the second half. The company now expects revenue in the range of $47.4 billion to $48.1 billion (6% to 8% reported growth) and adjusted EPS between $24.93 and $25.33 (9% to 11% growth). Full-year organic revenue growth is expected to be at the upper end of the 3% to 4% range, increasing from 3% in the first half to 4% in the second half. Q3 adjusted EPS is projected to be $0.35 to $0.40 higher than Q2. The improved outlook is primarily driven by pharma and biotech, while the academic and government market is expected to continue a stabilization period. Pharma Services (Patheon) is anticipated to have a stronger second half due to production schedules and reshoring wins.	AI	Accelerated drug development, population scale research, precision medicine, and reshoring of pharmaceutical manufacturing are emerging as significant trends. The increasing demand for safety and security applications globally is also noted.	We delivered an outstanding quarter. Customer activity across our end markets continue to strengthen. Our proven growth strategy is enhancing our capabilities, further advancing our trusted partner status with customers and continuing to drive share gain. We are raising our guidance for the full year on the top and bottom line. Clinical research really had an excellent quarter. Biotech, clearly, we saw spending pick up. It was nice to see in the quarter that academic and government return to growth. Bioproduction had a really excellent quarter. Innovation is the most important driver. Very nice performance for analytical instruments in Q2. Great to return to growth in the business. There's a lot of excitement about our pipelines. The bioproduction space is a great space.	China growing low single digits. Academic and Government within China remains quite muted, not different than what we've seen, but not improving either. We still think the market is going through a stabilization period. It's not accretive to our organic growth as a company yet. The first quarter had very specific headwinds. It doesn't necessarily imply that this fourth quarter grows over the third quarter.

2026-04-23

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Thermo Fisher completed the acquisition of Clario, a market leader in digital endpoint data solutions, which enhances its ability to serve pharma and biotech customers by enabling deeper clinical insights and improving drug development productivity. The company also formed a strategic collaboration with NVIDIA to commercialize new AI-enabled workflow solutions for scientific instrumentation. A collaboration with SHL Medical aims to strengthen U.S. drug product manufacturing capabilities, leveraging the recently acquired Ridgefield, New Jersey Sterile fill-finish site to offer integrated sterile fill-finish and device assembly solutions. Thermo Fisher opened a new Cryo-EM Drug Discovery Center in San Francisco to accelerate the adoption of advanced Cryo-EM technologies for drug development. New product launches include the Thermo Scientific Glacios 3 Cryo-TEM with AI-enabled workflows, democratizing access to cryo-EM; the Thermo Scientific TSQ Certis Triple Quad Mass Spectrometer for enhanced productivity in pharmaceutical and applied markets; the Thermo Scientific Niton XL5E handheld XRF analyzer for industrial and applied customers; the Gibco CTS Compleo fill and finish system for automated cell therapy manufacturing; and FluidEase Pro ClipTip electronic pipettes for improved lab efficiency.	Thermo Fisher continues to strengthen its leadership position as a trusted partner to customers, leveraging its global scale and PPI Business System. The company's high-impact innovation and industry-leading commercial engine are key competitive advantages. The unique accelerated drug development offering, combining pharma services and clinical research capabilities, is a competitive differentiator leading to strong performance and share gains in the clinical research business. The Clario acquisition further strengthens Thermo Fisher's position as a trusted partner to pharma and biotech customers. Management noted continued share gain momentum in Clinical Research. AI is expected to accelerate and enhance Thermo Fisher's durable competitive advantage. In China, pharma and biotech customers see Thermo Fisher's technology and capabilities as a differential advantage when competing with other Chinese companies. The research and safety market channel is benefiting from both improving end-market conditions and market share gains.	End markets are progressing as expected, though the broader macroeconomic environment has added complexity due to the conflict in the Middle East, which is anticipated to create modest inflationary pressure. Customers remain focused on advancing their priorities, and end markets are expected to prove resilient. The biotech funding environment is improving, leading to stronger sentiment and good opportunities. Artificial intelligence is seen as a significant positive for the industry, accelerating scientific discovery, deepening understanding, and ultimately speeding up the delivery of new medicines to patients by improving returns on investment for the drug development industry. Reshoring activity is noted as a 'nice tailwind' for the 2027-2028 timeframe, with real momentum and signed contracts in the CDMO and bioproduction businesses.	Thermo Fisher is raising its full-year 2026 guidance for both revenue and adjusted EPS, incorporating the positive impact of the Clario acquisition and strong Q1 performance. The new revenue guidance is $47.3 billion to $48.1 billion, representing 6% to 8% reported growth and 3% to 4% organic growth over 2025. Adjusted EPS is now expected to be in the range of $24.64 to $25.12, reflecting 8% to 10% growth over 2025. The company anticipates approximately 3% organic revenue growth for Q2 2026, with Q2 adjusted EPS expected to be $0.25 to $0.30 higher than Q1. For the U.S. academic and government market, greater stability is assumed, with modest improvement over time but not a return to normal conditions. No meaningful growth is assumed for China this year, but a return to stronger growth in the future would be an incremental tailwind. The company is actively working to mitigate higher inflation assumed for future quarters.	CROs:	AI adoption at scale for operational efficiency within the company (PPI Business System) and for accelerating scientific discovery and drug development across the industry. Digital transformation of clinical research, exemplified by the Clario acquisition and its focus on digital endpoint data solutions. Reshoring and regionalization of biopharma manufacturing and supply chains, particularly in the U.S., driven by customer needs and government initiatives. Ongoing inflationary pressures influenced by geopolitical conflicts.	We delivered a strong start to the year. Our end markets are progressing in line with our expectations. Our progress in the quarter further advances our leadership position. We delivered mid-single-digit growth during the quarter. (Pharma and biotech) We delivered another quarter of strong growth in our transplant diagnostics business. Our innovation enables customers to advance science and improve lives. Clario is an outstanding strategic fit. The business is performing very well. (Filtration and separation) We are raising our guidance for the full year. Clinical Research has had an excellent quarter. Biotech environment is improving from a funding perspective. AI is playing with our customers, it's accelerating scientific discovery. Reshoring activity, it's actually a nice tailwind. Bioproduction business had a phenomenal quarter. I actually left China incrementally more positive.	Academic and government, revenue declined low single digits. Diagnostics and Health Care, revenue declined in the mid-single digits. Broader macroeconomic environment, there is added complexity. Analytical Instruments segment... organic revenue decreased 2% year-over-year. The majority of the margin change was driven by the expected impacts of tariffs and related FX. Specialty Diagnostics... organic revenue declined 3%. Assumption for higher inflation in future quarters. China declining low single digits. Not assuming any meaningful growth coming out of China this year.	The company's drug product site in Cincinnati, Ohio, would benefit from growth in jobs due to reshoring initiatives.

2026-01-29

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Thermo Fisher is significantly expanding its footprint in the clinical research and manufacturing sectors through the $9 billion acquisition of Clario, a leader in digital endpoint data solutions. They also completed the acquisition of a filtration and separation business from Sorventum and a sterile fill-finish site from Sanofi in New Jersey to support reshoring trends. Additionally, the company expanded its global footprint with new bioprocess design centers in India and launched the five-liter DynaDrive single-use bioreactor to scale manufacturing of new therapies.	Management highlighted that the company continues to drive 'meaningful share gains' across its end markets. Marc Casper described the company as a 'methodical share gainer over many years' and noted that their 'trusted partner status' and 'unparalleled commercial engine' are key competitive advantages. Despite macro pressures, their share position in academic and government sectors remained stable, and they are winning contracts specifically for pharmaceutical reshoring to the U.S.	The industry is seeing a recovery in early research demand and a positive shift in biotech funding sentiment, though a lag exists before this translates to spending. The pharma and biotech sector showed high single-digit growth in Q4. However, the broader industry faces headwinds from macro conditions in China (which declined mid-single digits for the year) and cautious academic/government spending in the U.S. due to budget uncertainties. AI is emerging as a major force, with the industry moving toward a 'wet lab/dry lab' combination to improve R&D efficiency.	For 2026, TMO initiated revenue guidance of $46.3B to $47.2B, assuming 3% to 4% organic growth. Adjusted EPS is projected at $24.22 to $24.80 (6% to 8% growth). The Clario acquisition, expected to close by mid-2026, is anticipated to add an incremental $0.20 to $0.25 to EPS. Management expects Q1 organic growth to be a couple of points lower than the full year due to selling days and pharma services phasing, but they remain optimistic about market conditions improving as the year progresses.	Lab	Digital transformation of clinical research via digital endpoints; AI-driven productivity in drug development; Reshoring and regionalization of sterile manufacturing; Sustainability in lab operations (zero-waste certification).	"We enter 2026 from a position of strength as the market leader."; "The tone was incredibly positive... funding is starting to improve."; "Methodical share gainer over many years and that trend continues."; "2025 was another outstanding year of innovation."	"China declining mid single digits."; "Performance in this end market was impacted by the macro conditions in the US and China."; "Q1 organic revenue growth will be a couple of points lower than the full year."; "Headwind from tariffs and related FX of over 100 basis points."

2026-01-29

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Thermo Fisher is significantly expanding its footprint in the clinical research and manufacturing sectors through the $9 billion acquisition of Clario, a leader in digital endpoint data solutions. They also completed the acquisition of a filtration and separation business from Sorventum and a sterile fill-finish site from Sanofi in New Jersey to support reshoring trends. Additionally, the company expanded its global footprint with new bioprocess design centers in India and launched the five-liter DynaDrive single-use bioreactor to scale manufacturing of new therapies.	Management highlighted that the company continues to drive 'meaningful share gains' across its end markets. Marc Casper described the company as a 'methodical share gainer over many years' and noted that their 'trusted partner status' and 'unparalleled commercial engine' are key competitive advantages. Despite macro pressures, their share position in academic and government sectors remained stable, and they are winning contracts specifically for pharmaceutical reshoring to the U.S.	The industry is seeing a recovery in early research demand and a positive shift in biotech funding sentiment, though a lag exists before this translates to spending. The pharma and biotech sector showed high single-digit growth in Q4. However, the broader industry faces headwinds from macro conditions in China (which declined mid-single digits for the year) and cautious academic/government spending in the U.S. due to budget uncertainties. AI is emerging as a major force, with the industry moving toward a 'wet lab/dry lab' combination to improve R&D efficiency.	For 2026, TMO initiated revenue guidance of $46.3B to $47.2B, assuming 3% to 4% organic growth. Adjusted EPS is projected at $24.22 to $24.80 (6% to 8% growth). The Clario acquisition, expected to close by mid-2026, is anticipated to add an incremental $0.20 to $0.25 to EPS. Management expects Q1 organic growth to be a couple of points lower than the full year due to selling days and pharma services phasing, but they remain optimistic about market conditions improving as the year progresses.	Lab	Digital transformation of clinical research via digital endpoints; AI-driven productivity in drug development; Reshoring and regionalization of sterile manufacturing; Sustainability in lab operations (zero-waste certification).	"We enter 2026 from a position of strength as the market leader."; "The tone was incredibly positive... funding is starting to improve."; "Methodical share gainer over many years and that trend continues."; "2025 was another outstanding year of innovation."	"China declining mid single digits."; "Performance in this end market was impacted by the macro conditions in the US and China."; "Q1 organic revenue growth will be a couple of points lower than the full year."; "Headwind from tariffs and related FX of over 100 basis points."

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-01-29	Thermo Fisher delivered a Q4 beat, but shares fell 4.8% as the market focused on a cautious 2026 organic growth outlook of 3-4%. While management highlighted bioprocessing recovery and the $9 billion Clario acquisition, investors were likely spooked by a slow Q1 forecast and ongoing tariff-related headwinds. The stock's 11% decline since the call reflects skepticism regarding the pace of the industry rebound despite management's optimistic messaging.	Earnings Transcript	Bearish	https://ir.thermofisher.com/investors/news-and-events/events-and-presentations/default.aspx	-4.84% (vs SPY: -4.84%)

Upcoming Events6 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
TMO_81c2f485	future quarters	2026-07-01	2026-12-31	Impact of higher-than-expected inflation on operating costs and margins.	Management has included a placeholder for potential unmitigated inflation. If inflation is higher than assumed or mitigation efforts are less effective, it could negatively impact adjusted operating margins and EPS, potentially leading to a miss on guidance.	Ticker	2026-04-23	earnings_transcript
TMO_02e98b8e	on track, and the integration is progressing well	2026-04-23	2027-12-31	Successful integration and financial performance of the recently acquired Clario business, including earn-out payments tied to 2026 and 2027 results.	Clario is expected to add $900 million in revenue and $0.32 to adjusted EPS for 2026. Any challenges in integration or underperformance could materially impact TMO's updated guidance and investor sentiment.	Ticker	2026-04-23	earnings_transcript
TMO_00e34c04	Q2	2026-04-01	2026-09-30	Achievement of the projected acceleration in organic revenue growth, particularly in Q2 and the second half of 2026.	The full-year guidance assumes a significant ramp in organic growth from Q1's 1%. Failure to meet this acceleration could lead to a miss on full-year revenue and EPS guidance, negatively impacting investor sentiment.	Ticker	2026-04-23	earnings_transcript
TMO_de6c0f26	improving from a funding perspective	2026-04-23	2026-12-31	Continued translation of improving biotech funding into increased customer spending and authorizations for clinical research and bioproduction.	Increased biotech spending is a key driver for TMO's pharma and biotech end market, particularly for clinical research and bioproduction. A stronger translation could lead to upside in revenue and bookings.	Theme	2026-04-23	earnings_transcript
TMO_fb08b92a	Q2	2026-04-01	2026-12-31	Recovery in demand for Analytical Instruments and improved spending from academic and government customers in the U.S. and China.	Muted demand in these segments has been a drag on performance. A stronger-than-expected recovery or normalization could provide an upside to TMO's revenue and segment profitability.	Ticker	2026-04-23	earnings_transcript
TMO_3fae1221	over time	2026-07-01	2026-12-31	A return to stronger growth in the China market, beyond the current muted expectations.	China is a significant market for TMO, and a return to stronger growth, not currently factored into guidance, would provide an incremental tailwind and upside to overall revenue.	Ticker	2026-04-23	earnings_transcript